The state of North Carolina currently has 12 active clinical trials seeking participants for NASH - Nonalcoholic Steatohepatitis research studies. These trials are conducted in various cities, including Durham, Winston-Salem, Charlotte and Chapel Hill.
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Recruiting
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/22/2024
Locations: Akero Clinical Study Site, Fayetteville, North Carolina +4 locations
Conditions: NASH/MASH, NAFLD/MASLD
Statins for the Treatment of NASH
Recruiting
The purpose of this research study is to determine whether the study drug, atorvastatin (Lipitor®), is safe and effective in improving the features of NASH.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
04/08/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: NASH - Nonalcoholic Steatohepatitis
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/02/2024
Locations: Akero Clinical Study Site, Fayetteville, North Carolina +4 locations
Conditions: NASH With Fibrosis, MASH With Fibrosis
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
Recruiting
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Lucas Research, Morehead City, North Carolina
Conditions: NASH, Cirrhosis, Liver
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
Recruiting
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis (MONARCH)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/01/2024
Locations: Site #464, Morehead City, North Carolina
Conditions: Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis
Recruiting
A study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with Nonalcoholic steatohepatitis (NASH).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/29/2024
Locations: JAVARA, Inc. / Tryon Medical Partners, PLLC, Charlotte, North Carolina +1 locations
Conditions: NASH
Nonalcoholic Fatty Liver Disease in HIV Database
Recruiting
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions associated with fat accumulation that ranges from benign, non-progressive liver fat accumulation to severe liver injury, cirrhosis, and liver failure. The spectrum of NAFLD encompasses simple nonalcoholic steatosis (nonalcoholic fatty liver [NAFL]) and nonalcoholic steatohepatitis (NASH) in which there is evidence of hepatocellular injury and/or fibrosis. NAFLD is the most common liver disease in adults and the second lea... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2024
Locations: Duke University, Durham, North Carolina
Conditions: NAFLD, NASH - Nonalcoholic Steatohepatitis, Hiv
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Charlotte Gastroenterology and Hepatology - Randolph Road Office, Charlotte, North Carolina +6 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
Androgens and NAFLD Longitudinal Cohort Study
Recruiting
The researchers want to learn how androgens, a type of sex hormone, might affect nonalcoholic fatty liver (NAFLD) in young women over time. NAFLD happens when fat builds up in the liver which can cause damage to the liver such as inflammation or scarring. Young women with a condition called polycystic ovary syndrome (PCOS) have a high risk for NAFLD, and they often have high androgen levels too. So the researchers are recruiting young women with PCOS as well as those without PCOS, and will comp... Read More
Gender:
Female
Ages:
Between 18 years and 40 years
Trial Updated:
01/19/2024
Locations: Duke University, Durham, North Carolina
Conditions: PCOS, NAFLD, NASH
A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH)
Recruiting
This is a safety study to evaluate BOS-580 administered subcutaneously over 12 weeks in Part A or 24 weeks in Part B.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/04/2024
Locations: Coastal Research Institute, LLC, Fayetteville, North Carolina +1 locations
Conditions: Nonalcoholic Steatohepatitis (NASH)
Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects
Recruiting
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
10/23/2023
Locations: UNC Health Care System, Chapel Hill, North Carolina +3 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
Recruiting
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Lucas Research - Diabetes & Endocrinology Consultants, PC, Morehead City, North Carolina
Conditions: Non Alcoholic Steatohepatitis (NASH)